GENOMIC INSTABILITY
December 8, 2023(NRF2) (ACTIVATOR | ACTIVATORS | ACTIVATION)
December 8, 2023- The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
- GLP-1 agonist to treat obesity and prevent Cardiovascular Disease: what have we achieved so far?
- The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size
- Effects of the GLP‐1 agonist Exendin‐4 on intravenous ethanol self‐administration in mice
- GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study
- Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and …
- GLP-1 agonist treatment: implications for diabetic retinopathy screening
- The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
- … of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide: Involvement of …
- Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis
- Sustained release GLP-1 Agonist PT320 delays disease progression in a mouse model of Parkinson’s disease
- Efficacy of GLP-1 agonist therapy in autosomal dominant WFS1-related disorder: a case report
- SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM
- Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients
- Peptide oligomerization memory effects and their impact on the physical stability of the GLP-1 agonist liraglutide
- Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner
- Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice
- Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages
- Lixisenatide: a new daily GLP-1 agonist for type 2 diabetes management
- Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice
- Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist
- Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at …
- The evolving world of GLP-1 agonist therapies for type 2 diabetes
- (Val8)GLP‐1‐Glu‐PAL: a GLP‐1 Agonist That Improves Hippocampal Neurogenesis, Glucose Homeostasis, and β‐Cell Function in High‐Fat‐Fed Mice
- GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects
- Addition of SGLT2 inhibitor to GLP‐1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control
- GLP-1 agonist Liraglutide prevents MK‑801–induced schizophrenia‑like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontal …
- Crystal structure of the GLP-1 receptor bound to a peptide agonist
- Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- Effects of GLP-1 agonist exenatide on cardiac diastolic function and vascular endothelial function in diabetic patients
- Rybelsus: an oral formulation of the GLP‐1 agonist semaglutide
- Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures
- Liraglutide: once‐daily GLP‐1 agonist for the treatment of type 2 diabetes
- Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer’s disease
- The impact of exenatide (a GLP‑1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic …
- Beneficial effects of GLP-1 agonist in a male with compulsive food-related behavior associated with autism
- The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic …
- The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats
- Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
- Oral self-nanoemulsifying formulation of GLP-1 agonist peptide exendin-4: development, characterization and permeability assesment on Caco-2 cell monolayer
- A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
- A GLP‐1/glucagon (GCG)/CCK2 receptors tri‐agonist provides new therapy for obesity and diabetes
- Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats
- Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway
- The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice
- The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy
- Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes
- Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: A …
- Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates
- The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials
- MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, phase 1 study
- Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 …
- The novel GLP‐1‐gastrin dual agonist, ZP3022, increases β‐cell mass and prevents diabetes in db/db mice
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− …
- Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a …
- The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse …
- Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
- Role of renal sympathetic nerves in GLP‐1 (glucagon‐like peptide‐1) receptor agonist exendin‐4‐mediated diuresis and natriuresis in diet‐induced obese rats
- The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes
- Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes
- A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model
- Adherence to GLP-1 agonist therapy in US managed care
- Acute pancreatitis during GLP-1 receptor agonist treatment. A case report
- Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice
- Corrination of a GLP-1 receptor agonist for glycemic control without emesis
- The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats
- Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use
- GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats
- Long-Acting Glucagon-Like Peptide-1 (GLP-1) Agonist Therapy in Post Solid Organ Transplant Patients.: Abstract# B913
- Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations
- Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use
- The use of GLP-1 agonist therapy, liraglutide, is associated with significant weight loss in morbidly obese people without diabetes
- Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese …
- Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder
- Dapiglutide, a novel dual GLP‐1 and GLP‐2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel
- Semaglutide (GLP‐1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral …
- Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent
- S2868 autoimmune hepatitis-like drug injury of the liver associated with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide
- Long-acting GLP-1 receptor agonist exenatide influence on the autonomic cardiac sympatho-vagal balance
- Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats
- A GLP-1 receptor agonist inhibits aldosterone release in healthy volunteers
- GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3β pathway
- Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
- Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying–preclinical evidence
- Lowest glucose variability and hypoglycemia are observed with the combination of a GLP-1 receptor agonist and basal insulin (VARIATION Study)
- Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide
- Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes
- Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly …
- Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL …
- The use of liraglutide, a GLP-1 agonist, in obese people with type 1 diabetes
- GSK2374697, a long duration glucagon‐like peptide‐1 (GLP‐1) receptor agonist, reduces postprandial circulating endogenous total GLP‐1 and peptide YY in healthy …
- The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice …
- IDF2022-1118 A comparative effect of DPP4 inhibitor and GLP-1 agonist on lipid profile among obese patients with DMT2
- Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP
- A novel antihypertensive effect of exenatide, a GLP-1 agonist
- Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects
- Combining SGLT2 inhibitor and GLP-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes
- Glucagon and a glucagon‐GLP‐1 dual‐agonist increases cardiac performance with different metabolic effects in insulin‐resistant hearts
- Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo …
- The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
- Efficacy and safety of basal insulin/GLP-1 receptor agonist used in combination for type 2 diabetes management
- GLP-1 agonist use in a patient with an explainable cause of pancreatitis
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending …
- A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
- Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single …
- Profound weight reduction with GLP‐1 agonist therapy: a delayed hyper‐response
- Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to …
- A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain
- … Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with …
- Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal …
- The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and …
- Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew)
- Exendin-4, a GLP-1 receptor agonist, interacts with proteins and their products of digestion to suppress food intake in rats
- Oral semaglutide: first-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus
- Systemic allergic reaction to the GLP-1 receptor agonist exenatide
- Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes
- Tirzepatide—a dual GIP/GLP-1 receptor agonist—a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
- The Efficacy of the GLP-1 Agonist Exenatide in the Treatment of Short Bowel Syndrome: 233
- A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′ s disease by increasing expression of BNDF
- Glucagon-Like Peptide-1 (GLP-1) Agonist
- Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice
- Indices of beta‐cell function: association with diabetes control in patients with type 2 diabetes on stable GLP‐1 agonist treatment
- ACUTE PANCREATITIS AND TYPE 2 DIABETES MELLITUS: GLP-1 RECEPTOR AGONIST OR IDIOPATHIC, A DIAGNOSTIC DILEMMA, A CASE REPORT WITH …
- PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease
- … Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With …
- GLP-1 agonist protects myocardial hypoxia-reoxygenation injury through PI3K/Akt signaling pathway: an experimental study
- Drug-induced Liver Injury Associated with the Glucagon-like Peptide 1 (GLP-1) Agonist Liraglutide: 1131
- Hemochromatosis and cystic fibrosis carriers identify risk for GLP-1 agonist associated Pancreatitis
- Exendin-4, a GLP-1 receptor agonist, modulates the effect of macronutrients on food intake by rats
- Off target benefits of GLP-1 agonist therapy in type 2 diabetes
- 2136-PUB: GLP-1 agonist exendin-4 protects endothelial cells against hyperhomocysteinemia by alleviating ER stress and enhancing protein folding machinery
- Cellulitis at GLP-1 Agonist Injection Site: Rare But Relevant
- Off-label GLP-1 agonist treatment in 43 non-diabetic patients: are weight loss and treatment tolerance equally promising outside of clinical trials?
- The effect of the GLP-1 agonist, liraglutide, on the right ventricle in pulmonary hypertension
- Ozempic–another GLP-1 agonist coming real soon
- The GLP-1 receptor agonist Exendin-4 modulates hippocampal NMDA-receptor signalling in aged rats and improves cognitive impairment in diabetic elderly …
- A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist
- Sustained release subcutaneous delivery of BMS-686117, a GLP-1 receptor peptide agonist, via a zinc adduct
- Sglt-2 Inhibition Added to Glp-1 Agonist Therapy for Type 2 Diabetes: What is the Benefit?
- The use of GLP-1 agonist in an adolescent with type 1 diabetes mellitus and obesity
- Deaths stalk GLP-1 agonist
- GLP-1 agonist liraglutide increases metabolic-and cardiovascular-related sympathetic activity of the central nervous system.
- Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity
- Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients
- Cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonist based on race, ethnicity, and gender: A systematic review and meta-analysis of randomized trials
- Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one?
- USE OF GLP-1 AGONIST EXENATIDE TO TREAT REACTIVE HYPOGLYCEMIA AFTER GASTIC BYPASS SURGERY
- 1027-P: Lower Admission HbA1c Is Associated with Lower Likelihood of SGLT-2 Inhibitor or GLP-1 Agonist Prescription in Patients with Type 2 Diabetes after …
- Is there sustained weight loss after discontinuation of GLP-1 agonist for obesity treatment?
- The GLP‐1 agonist liraglutide lowers blood pressure in a placental ischemic model of preeclampsia
- Combined GIP/GLP-1 Agonist: Safe for Type 2 Diabetes Patients?
- Nutritional insulin or Glp-1 receptor agonist: crossroads in the treatment of type 2 diabetes mellitus
- Pharmacotherapy for Weight Loss in Cirrhosis: A Case Series of GLP-1 Agonist-associated Weight Loss
- Effect of GLP-1 agonist Exenatide on cerebral, hepatic and peripheral glucose metabolism in postprandial state
- Effect of GLP-1 agonist on osteoblast proliferation and related signaling pathways
- 130-OR: The Association between High Out-of-Pocket Costs and Incidence of Treatment Intensification with an SGLT2 Inhibitor (SGLT2i) or GLP-1 Agonist (GLP-1a) in …
- GLP‐1 AGONIST LIRAGLUTIDE ACTIVATES METABOLIC‐AND CARDIOVASCULAR‐RELATED HYPOTHALAMIC NEURONS AND AUGMENTS REFLEX …
- 4CPS-005 GLP-1 agonist liraglutide as add-on therapy in type 2 diabetes
- Liraglutide, GLP-1 receptor agonist, for chronic weight loss
- THE IMPACT OF GLUCAGON LIKE PEPTIDE-1 AGONIST THERAPY ON HEART RATE IN ADVANCED SYSTOLIC HEART FAILURE: AN ANALYSIS FROM THE …
- Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a …
- 350-OR: A Novel Long-Acting GLP-1 Agonist (GL0034) Demonstrates Remarkable Efficacy on HbA1c, Weight Loss, and Triglycerides in a Model of Type 2 Diabetes …
- Overcoming Therapeutic Inertia in Type 2 Diabetes: Combination GLP-1 Agonist and SGLT-2 Inhibitor Therapy Offers Hope
- GLP-1 Receptor Agonist Inhibited the Activation of RIPK1 for Alleviation the Neuronal Death and Neuroinflammation in APP/PS1 Mice
- Activity-Balanced GLP-1/GDF15 Dual Agonist to Treat Obesity in Mice and Non-Human Primates
- 1800-P: Cotadutide, a GLP-1/GCG Receptor Co-Agonist, Improves Insulin Sensitivity and Restores Normal Insulin Secretory Capacity in DIO Mice
- … Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With …
- Meta-Analysis of GLP-1 Receptor Agonist Lixisenatide Use in Patients Insufficiently Controlled with Oral Antihyperglycemic Agents
- Could 99mTc labeled long-acting agonist of GLP-1 (Exendin-4) scintigraphy be a new tool in the diagnostics of unknown focus of insulinoma? preliminary results
- Diabetic cases controlled with low carbohydrate diet (LCD) and GLP-1 receptor agonist (GLP-1 RA)
- Hemodynamic effect of a single dose of glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide in patients with diabetic kidney disease.
- Evaluation of a combination of SGLT2 inhibitor and GLP-1 receptor agonist treatment in type 2 diabetes
- Reduction of Angiotensin II Induced Hypertension and Cardiac Fibrosis with GLP-1 Receptor Agonist and DPP-4 Inhibitor via Decreasing NADPH Oxidase Expression
- Potential role of GLP-1 receptor agonist in a rat model of cardio-renal syndrome type-3: effects on oxidative, inflammatory and inos expression axis
- Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes
- Master Thesis: EFFECT OF GLP-1 RECEPTOR AGONIST, EXERCISE, AND HIGH-FAT DIET ON VARIATION IN BODY WEIGHT, BLOOD GLUCOSE LEVELS …
- Effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cardiac structure and function: a systematic review and meta-analysis of randomized-controlled trials
